RxDoctor Payments Data

Edwin Whitney, MD

Cardiovascular Disease · San Antonio, TXNPI 1669563656

Payments from drug & device makers

$30,485in general payments, 2019–2025

Across 235 payments — averaging $129.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$16K
  • Lilly USA, LLC$10K
  • Novartis$824
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$553
  • Novo Nordisk$483
  • Johnson & Johnson$450
  • plus $2K from 13 others

What the payments were for

  • Consulting fees$4,12514%
  • Speaking & faculty fees$19,38864%
  • Travel & lodging$1,5665%
  • Food & beverage$5,29117%
  • Education$1150%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,485 in reported general payments places this provider in the 80th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$381,320
Medicare patients
997
Services billed
4,746

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban469$560,102
OzempicSemaglutide462$545,269
JardianceEmpagliflozin420$440,126
Repatha SureclickEvolocumab197$173,075
EntrestoSacubitril/Valsartan90$97,074
XareltoRivaroxaban56$83,592
MounjaroTirzepatide61$72,456
TrulicityDulaglutide39$44,004
Praluent PenAlirocumab61$40,352
Colchicine586$38,811
CorlanorIvabradine Hcl48$25,939
CyclosetBromocriptine Mesylate37$19,525
VascepaIcosapent Ethyl35$19,062
Rosuvastatin Calcium1,248$16,117
Repatha SyringeEvolocumab22$16,016

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$183$560,102469 claims
Novo NordiskOzempic$483$545,269462 claims
Boehringer IngelheimJardiance, Spiriva Respimat$16,188$454,635439 claims
Lilly USA, LLCMounjaro, Trulicity$10,328$116,460100 claims
NovartisEntresto$824$97,07490 claims
Johnson & JohnsonXarelto$450$83,59256 claims
AmgenCorlanor$16$25,93948 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCCycloset$553$19,52537 claims
MerckJanuvia$89$15,72614 claims
Esperion Therapeutics, Inc.Nexlizet$278$9,06313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →